CHRU enrols first patient in an HIV cure trial

We’re thrilled to announce that the Clinical HIV Research Unit (CHRU) in Johannesburg, South Africa has enrolled the first patient in the ACTG ACACIA study (A5417).

This marks a significant milestone in the global effort to explore HIV cures.

The ACACIA study evaluates two long-acting broadly neutralising antibodies (bNAbs), 3BNC117-LS and 10-1074-LS, administered at the start of HIV treatment to see if they can help control the virus in the absence of antiretroviral therapy. This is part of a groundbreaking Phase 2 trial across four African countries to advance HIV treatment and to find a cure.

Congratulations to the team at CHRU in Johannesburg!

ENDS

For further information, interviews please contact Turquoise PR:

• Isadora Isaacs +27 83 925 9676 isadora@turquoisepr.co.za
• Michelle K Blumenau +27 83 273 9891 michelle@turquoisepr.co.za

‍

‍